Smoking cessation in patients with respiratory diseases:: a high priority, integral component of therapy

被引:151
作者
Tonnesen, P.
Carrozzi, L.
Fagerstrom, K. O.
Gratziou, C.
Jimenez-Ruiz, C.
Nardiri, S.
Viegi, G.
Lazzaro, C.
Campell, I. A.
Dagli, E.
West, R.
机构
[1] Gentofte Univ Hosp, Dept Pulm Med, DK-2900 Copenhagen, Denmark
[2] Univ Hosp Pisa, Cardiopulm Dept, Pisa, Italy
[3] CNR, Pulm Environm Epidemiol Unit, Inst Clin Physiol, I-56100 Pisa, Italy
[4] Smoking Cessat Clin Vittorio Veneto, Milan, Italy
[5] Pharmacoecon & Hlth Econ Res & Consulting, Econ Evaluat Hlth Care Programmes, Milan, Italy
[6] Smokers Informat Ctr, Helsingborg, Sweden
[7] Univ Athens, Sch Med, Smoking Cessat Clin, Evgenidio Hosp, GR-11527 Athens, Greece
[8] Inst Publ Hlth, Smokers Clin, Madrid, Spain
[9] Llandough Hosp, Penarth, S Glam, Wales
[10] UCL, Canc Res UK Hlth Behav Unit, Dept Epidemiol & Publ Hlth, London, England
[11] Marmara Univ, Fac Med, Istanbul, Turkey
关键词
chronic obstructive pulmonary disease; guidelines; respiratory patients; smoking cessation;
D O I
10.1183/09031936.00060806
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Smoking cessation is the one of the most important ways to improve the prognosis of patients with respiratory disease. The Task Force on guidelines for smoking cessation in patients with respiratory diseases was convened to provide evidence-based recommendations on smoking cessation interventions in respiratory patients. Based on the currently available evidence and the consensus of an expert panel, the following key recommendations were made. 1) Patients with respiratory disease have a greater and more urgent need to stop smoking than the average smoker, so respiratory physicians must take a proactive and continuing role with all smokers in motivating them to stop and in providing treatment to aid smoking cessation. 2) Smoking cessation treatment should be integrated into the management of the patient's respiratory condition. 3) Therapies should include pharmacological treatment (i.e. nicotine replacement therapy, bupropion or varenicline) combined with behavioural support. 4) Respiratory physicians should receive training to ensure that they have the knowledge, attitudes and skills necessary to deliver these interventions or to refer to an appropriate specialist. 5) Although the cost of implementing these recommendations will partly be offset by a reduction in attendance for exacerbations etc. a budget should be established to,, enable implementation. Research is needed to establish optimum treatment strategies specifically for respiratory patients.
引用
收藏
页码:390 / 417
页数:28
相关论文
共 226 条
[81]  
Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244
[82]  
Fiore MC., 2000, TREATING TOBACCO USE
[83]  
Flanders WD, 2003, CANCER RES, V63, P6556
[84]   NATURAL-HISTORY OF CHRONIC AIR-FLOW OBSTRUCTION [J].
FLETCHER, C ;
PETO, R .
BMJ-BRITISH MEDICAL JOURNAL, 1977, 1 (6077) :1645-1648
[85]  
Fletcher C, 1976, NATURAL HIST CHRONIC
[86]   Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43 000 adult male deaths and 35 000 controls [J].
Gajalakshmi, V ;
Peto, R ;
Kanaka, TS ;
Jha, P .
LANCET, 2003, 362 (9383) :507-515
[87]   Safety profile of bupropion for chronic obstructive pulmonary disease [J].
García-Río, F ;
Serrano, S ;
Mediano, O ;
Alonso, A ;
Villamor, J .
LANCET, 2001, 358 (9286) :1009-1009
[88]   Smoking cessation and the course of major depression: a follow-up study [J].
Glassman, AH ;
Covey, LS ;
Stetner, F ;
Rivelli, S .
LANCET, 2001, 357 (9272) :1929-1932
[89]   SMOKING CESSATION, CLONIDINE, AND VULNERABILITY TO NICOTINE AMONG DEPENDENT SMOKERS [J].
GLASSMAN, AH ;
COVEY, LS ;
DALACK, GW ;
STETNER, F ;
RIVELLI, SK ;
FLEISS, J ;
COOPER, TB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (06) :670-679
[90]  
Glover ED, 1997, AM J HEALTH BEHAV, V21, P310